Please login to the form below

Not currently logged in
Email:
Password:

Oramed completes USD 2m financing round

Oramed Pharmaceuticals, an Israeli-headquartered developer of oral insulin gel capsules, has closed a financing round of over USD 2m by private investors.

Oramed Pharmaceuticals, an Israeli-headquartered developer of oral insulin gel capsules, has closed a financing round of over USD 2m by private investors.

The placement was at USD 0.50 per share with a warrant priced at USD 0.75.

Oramed's CEO, Nadav Kidron, said: "This investment, at a premium to the market, ensures that Oramed has enough funds to reach completion of phase I trials, which we expect by mid-2008. We hope to complete our phase Ia trials shortly. This investment...allows the company to fully focus on its R&D efforts and complete its phase I product trials."

Oramed is currently developing an orally ingestible soft gel insulin capsule for the treatment of diabetes. The company says it is also pursuing the development of oral delivery solutions for other drugs and vaccines.

6th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

segmentation_pie_thumb.jpg
If you’re not thinking segmentation, you’re not thinking
Having a background in market research I’ve been lucky to work on a number of customer segmentations in my time but working in creative communications it is still too rare...
Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked
...

Infographics